Elicio Therapeutics, Inc. (ELTX) NASDAQ
12.53
+1.04(+9.05%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
12.53
+1.04(+9.05%)
Currency In USD
Address
451 D Street
Boston, MA 02210
United States of America (the)
Phone
857-209-0050
Website
Sector
Healthcare
Industry
Biotechnology
Employees
32
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Robert T. Connelly | Chief Executive Officer, President & Director | 980,700 | 1960 |
| Allen Richard Nissenson FACP | Founder & Independent Director | 52,500 | 1947 |
| Peter DeMuth | Chief Scientific Officer | 648,600 | 1987 |
| Preetam Shah | Chief Strategy & Financial Officer and Treasurer | 687,077 | 1973 |
| Christopher Haqq | Executive Vice President, Head of Research & Development and Chief Medical Officer | 750,000 | 1966 |
| Darrell J. Irvine | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | 0 | N/A |
| Esther Welkowsky | Senior Vice President of Clinical Development | 0 | N/A |
| Megan C. Filoon | General Counsel, Secretary & Compliance Officer | 0 | N/A |
| Joy Seymour | Vice President & Head of Regulatory Affairs | 0 | N/A |
| Thian Kheoh | Senior Vice President of Biometrics | 0 | N/A |
| Marc J. Wolfgang | Chief Technology Officer | 0 | N/A |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.